Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Interim Study Results Presented At ADA 2009: Exenatide Not Associated With Increased Rate Of Acute Pancreatitis Compared To Other Antidiabetic Drugs
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced interim results from a retrospective study including nearly 260,000 patients that showed the risk of acute pancreatitis among patients initiating therapy with BYETTA(R) (exenatide) injection was not increased compared to patients initiating other antidiabetic therapies. These findings were presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans.
generic viagra online
Swine Flu Update Issued On Monday 29 June 2009, Wales
-- 17 confirmed cases in Wales, with 0 new cases.
News of the day
President's Remarks Point To Value Of Pharmacists On Patient Care Teams
In remarks on health care reform to the American Medical Association"s (AMA) House of Delegates on Monday, President Barack Obama pointed to pharmacists" participation on "multidisciplinary rounds" as an "island of excellence" that should become the "standard in our health care system."
Public Health

Oral Rivaroxaban As Prevention For Symptomatic Venous Thromboembolism

In this study data from three studies comparing the new oral anticoagulant rivaroxaban against enoxaparin injected subcutaneously was assessed and conclusions drawn about effectiveness of both types of treatment. Rivaroxaban was started six to eight hours after surgery, whereas enoxaparin was injected the previous evening and then at six to eight hours following wound closure. Thereafter, both were administered every 24 hours in a double-dummy fashion: all patients received either placebo injections or placebo tablets. The results showed that of 9581 patients in the study across 487 centres in 38 countries rivaroxaban significantly reduced the incidence of symptomatic venous thromoembolism compared with enoxaparin (0.4% and 0.8% respectively) without an increase in the risk of major bleeding in patients undergoing elective hip and knee replacement surgery. Read the full text article. The Journal of Bone and Joint Surgery


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009